Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.69 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.59 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5912617 | 0.86 | F7 (0.75) | NR4A2PBRM1F7F3KDM4E | |
| SCHEMBL613332 | 0.86 | F7 (0.74) | NR4A2F7F3AVPR1AGPR84 | |
| SCHEMBL30392504 | 0.86 | F7 (0.74) | NR4A2F7F3AVPR1AGPR84 | |
| Ammonia Solution, Strong SCHEMBL4556453 | 0.84 | F7 (0.72) | NR4A2F7F3AVPR1AGPR84 | |
| SCHEMBL26204498 | 0.83 | NR4A2 (0.65) | NR4A2F7F3AVPR1AGPR84 | |
| SCHEMBL3181314 | 0.82 | NR4A2 (0.64) | NR4A2F7F3AVPR1AGPR84 | |
| SCHEMBL3094622 | 0.82 | NR4A2 (1.00) | NR4A2F7F3AVPR1AMAPT | |
| SCHEMBL13533538 | 0.82 | NR4A2 (0.64) | NR4A2F7F3AVPR1AGPR84 | |
| SCHEMBL3188134 | 0.82 | NR4A2 (0.64) | NR4A2F7F3AVPR1AGPR84 | |
| SCHEMBL17423792 | 0.81 | MAPT (0.64) | NR4A2F7F3AVPR1AGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2008006790-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| EP-0820441-B1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6358992-B1 | Method of inhibiting neoplastic cells with indole derivatives | CELL PATHWAYS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6069156-A | Indole derivatives as cGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-30 | — | — | US | disclosed |
| CN-1187812-A | Indole derivatives as CGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-07-15 | — | — | CN | disclosed |
| EP-0820441-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032379-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016371-A1 | Indole Compounds | IDO1, TPH1, IDO2 | NR4A2 3552/4885PBRM1 3715/4885F7 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.